nach oben

Digestive Diseases and Sciences

Erschienen in:

17.12.2018 | Original Article

Gut Microbiome, Short-Chain Fatty Acids, and Mucosa Injury in Young Adults with Human Immunodeficiency Virus Infection

verfasst von: Yong Qing, Hangyu Xie, Chen Su, Youwei Wang, Qiuyue Yu, Qiuyu Pang, Fan Cui

Erschienen in: Digestive Diseases and Sciences | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

HIV progression is characterized by immune activation and microbial translocation from the gut. Short-chain fatty acids (SCFAs) are essential for gut homeostasis. Decreased intestinal SCFAs play a role in rapid HIV progression.

Aims

To compare the SCFA profile, intestinal microbiome, and intestinal mucosal injury between patients with HIV (but not AIDS) and healthy controls.

Methods

This was a prospective study of 15 patients without AIDS and 10 controls conducted between July 2016 and January 2017 at the Institute of Dermatology and Venereology (Sichuan Academy of Medical Sciences). Stool specimens were collected to analyze the microbiome and SCFAs. Blood I-FABP and d-lactate (gut injury markers) were measured as well as T cells in HIV-positive patients. Intestinal mucosa was observed by colonoscopy.

Results

Rikenellaceae, Microbacteriaceae, Roseburia, Lachnospiraceae, Alistipes, and Ruminococcaceae were decreased, while Moraxellaceae and Psychrobacter were increased in HIV-positive patients. Butyric acid (p = 0.04) and valeric acid (p = 0.03) were reduced in HIV-positive patients. Colonoscopy revealed no visible damage in all subjects. There were no differences in I-FABP and d-lactate between groups. Butyric and valeric acids mainly positively correlated with Rikenellaceae, Ruminococcaceae, Alistipes, Roseburia, and Lachnospiraceae. CD8+ cells were positively correlated with Proteobacteria. CD4+ cells, and CD4/CD8 were negatively correlated with acetic acid. CD8+ cells were positively correlated with valeric acid.

Conclusion

The differences in the distribution of intestinal flora between HIV-infected and healthy individuals, especially some SCFAs, suggest that there is already a predisposition to intestinal mucosa damage in HIV-infected individuals.

Feinberg J. In the clinic. Management of newly diagnosed HIV infection. Ann Intern Med. 2011;155:ITC41.CrossRefPubMed

Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med. 2011;364:1943–1954.CrossRefPubMedPubMedCentral

Wilcox CM, Saag MS. Gastrointestinal complications of HIV infection: changing priorities in the HAART era. Gut. 2008;57:861–870.CrossRefPubMed

Li SX, Armstrong A, Neff CP, Shaffer M, Lozupone CA, Palmer BE. Complexities of gut microbiome dysbiosis in the context of HIV infection and antiretroviral therapy. Clin Pharmacol Ther. 2016;99:600–611.CrossRefPubMed

Chevalier MF, Petitjean G, Dunyach-Remy C, et al. The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog. 2013;9:e1003453.CrossRefPubMedPubMedCentral

Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol. 2008;46:757–758.CrossRefPubMed

Tincati C, Douek DC, Marchetti G. Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection. AIDS Res Ther. 2016;13:19.CrossRefPubMedPubMedCentral

Burgener A, McGowan I, Klatt NR. HIV and mucosal barrier interactions: consequences for transmission and pathogenesis. Curr Opin Immunol. 2015;36:22–30.CrossRefPubMed

Noguera-Julian M, Rocafort M, Guillen Y, et al. Gut microbiota linked to sexual preference and HIV infection. EBioMedicine. 2016;5:135–146.CrossRefPubMedPubMedCentral

10.

Dillon SM, Kibbie J, Lee EJ, et al. Low abundance of colonic butyrate-producing bacteria in HIV infection is associated with microbial translocation and immune activation. AIDS. 2017;31:511–521.CrossRefPubMed

11.

Nowak P, Troseid M, Avershina E, et al. Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS. 2015;29:2409–2418.CrossRefPubMed

12.

Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med. 2013;5:193ra191.CrossRef

13.

Zilberman-Schapira G, Zmora N, Itav S, Bashiardes S, Elinav H, Elinav E. The gut microbiome in human immunodeficiency virus infection. BMC Med. 2016;14:83.CrossRefPubMedPubMedCentral

14.

Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014;10:e1003829.CrossRefPubMedPubMedCentral

15.

Saxena D, Li Y, Devota A, et al. Modulation of the orodigestive tract microbiome in HIV-infected patients. Oral Dis. 2016;22 Suppl 1:73–78.CrossRefPubMed

16.

Serrano-Villar S, Rojo D, Martinez-Martinez M, et al. Gut bacteria metabolism impacts immune recovery in HIV-infected individuals. EBioMedicine. 2016;8:203–216.CrossRefPubMedPubMedCentral

17.

Tao JH, Duan JA, Jiang S, Guo JM, Qian YY, Qian DW. Simultaneous determination of six short-chain fatty acids in colonic contents of colitis mice after oral administration of polysaccharides from Chrysanthemum morifolium Ramat by gas chromatography with flame ionization detector. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1029–1030:88–94.CrossRefPubMed

18.

Das B, Dobrowolski C, Shahir AM, et al. Short chain fatty acids potently induce latent HIV-1 in T-cells by activating P-TEFb and multiple histone modifications. Virology. 2015;474:65–81.CrossRefPubMed

19.

Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe. 2015;17:662–671.CrossRefPubMedPubMedCentral

20.

Kim CH, Park J, Kim M. Gut microbiota-derived short-chain fatty acids, T cells, and inflammation. Immune Netw. 2014;14:277–288.CrossRefPubMedPubMedCentral

21.

Yuille S, Reichardt N, Panda S, Dunbar H, Mulder IE. Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. PLoS ONE. 2018;13:e0201073.CrossRefPubMedPubMedCentral

22.

Correa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol. 2016;5:e73.CrossRef

23.

Luhrs H, Gerke T, Muller JG, et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002;37:458–466.CrossRefPubMed

24.

Vazquez-Castellanos JF, Serrano-Villar S, Latorre A, et al. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol. 2015;8:760–772.CrossRefPubMed

25.

Villar-Garcia J, Guerri-Fernandez R, Moya A, et al. Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: a double-blind, randomised, placebo-controlled trial. PLoS ONE. 2017;12:e0173802.CrossRefPubMedPubMedCentral

26.

Ellis CL, Ma ZM, Mann SK, et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J Acquir Immune Defic Syndr. 2011;57:363–370.CrossRefPubMedPubMedCentral

27.

Ji Y, Zhang F, Zhang R, et al. Changes in intestinal microbiota in HIV-1-infected subjects following cART initiation: influence of CD4+ T cell count. Emerg Microbes Infect. 2018;7:113.CrossRefPubMedPubMedCentral

28.

Wang X, Wang J, Rao B, Deng L. Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017;13:2848–2854.CrossRefPubMedPubMedCentral

29.

Zhou Y, Ou Z, Tang X, et al. Alterations in the gut microbiota of patients with acquired immune deficiency syndrome. J Cell Mol Med. 2018;22:2263–2271.CrossRefPubMedPubMedCentral

30.

Travis AJ, Kelly D, Flint HJ, Aminov RI. Complete genome sequence of the human gut symbiont Roseburia hominis. Genome Announc. 2015;3:e01286–15.CrossRefPubMedPubMedCentral

31.

Jost T, Lacroix C, Braegger C, Chassard C. Assessment of bacterial diversity in breast milk using culture-dependent and culture-independent approaches. Br J Nutr. 2013;110:1253–1262.CrossRefPubMed

32.

Tamanai-Shacoori Z, Smida I, Bousarghin L, et al. Roseburia spp.: a marker of health? Future Microbiol. 2017;12:157–170.CrossRefPubMed

33.

Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–1283.CrossRefPubMed

34.

Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial composition in Parkinson’s disease. Mov Disord. 2015;30:1351–1360.CrossRefPubMed

35.

Hatziioanou D, Mayer MJ, Duncan SH, Flint HJ, Narbad A. A representative of the dominant human colonic Firmicutes, Roseburia faecis M72/1, forms a novel bacteriocin-like substance. Anaerobe. 2013;23:5–8.CrossRefPubMed

36.

Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55:205–211.CrossRefPubMedPubMedCentral

37.

Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett. 2009;294:1–8.CrossRefPubMed

38.

Meehan CJ, Beiko RG. A phylogenomic view of ecological specialization in the Lachnospiraceae, a family of digestive tract-associated bacteria. Genome Biol Evol. 2014;6:703–713.CrossRefPubMedPubMedCentral

39.

Reeves AE, Koenigsknecht MJ, Bergin IL, Young VB. Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect Immun. 2012;80:3786–3794.CrossRefPubMedPubMedCentral

40.

Sagheddu V, Patrone V, Miragoli F, Puglisi E, Morelli L. Infant early gut colonization by lachnospiraceae: high frequency of Ruminococcus gnavus. Front Pediatr. 2016;4:57.CrossRefPubMedPubMedCentral

41.

Graf J. The Family Rikenellaceae. In: Rosenberg E, DeLong EF, Lory S, Stackebrandt E, Thompson F, eds. The Prokaryotes. Berlin: Springer; 2014.

42.

Dziarski R, Park SY, Kashyap DR, Dowd SE, Gupta D. Pglyrp-regulated gut microflora Prevotella falsenii, Parabacteroides distasonis and Bacteroides eggerthii enhance and Alistipes finegoldii attenuates colitis in mice. PLoS ONE. 2016;11:e0146162.CrossRefPubMedPubMedCentral

43.

Zevin AS, McKinnon L, Burgener A, Klatt NR. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS. 2016;11:182–190.CrossRefPubMedPubMedCentral

44.

Klase Z, Ortiz A, Deleage C, et al. Dysbiotic bacteria translocate in progressive SIV infection. Mucosal Immunol. 2015;8:1009–1020.CrossRefPubMedPubMedCentral

45.

Teixeira LM, Merquior VLC. The Family Moraxellaceae. In: Rosenberg E, DeLong EF, Lory S, Stackebrandt E, Thompson F, eds. The Prokaryotes. Berlin: Springer; 2014.

46.

Saito R, Nonaka S, Nishiyama H, Okamura N. Molecular mechanism of macrolide-lincosamide resistance in Moraxella catarrhalis. J Med Microbiol. 2012;61:1435–1438.CrossRefPubMed

47.

Alcala L, Ruiz-Serrano MJ, Cosin J, Garcia-Garrote F, Ortega A, Bouza E. Disseminated infection due to Mycobacterium simiae in an AIDS patient: case report and review. Clin Microbiol Infect. 1999;5:294–296.CrossRefPubMed

48.

Michelini Z, Baroncelli S, Fantauzzi A, et al. Reduced plasma levels of sCD14 and I-FABP in HIV-infected patients with mesalazine-treated ulcerative colitis. HIV Clin Trials. 2016;17:49–54.CrossRefPubMed

49.

Smith SM, Eng RH, Campos JM, Chmel H. d-lactic acid measurements in the diagnosis of bacterial infections. J Clin Microbiol. 1989;27:385–388.PubMedPubMedCentral

50.

Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148:1258–1270.CrossRefPubMedPubMedCentral

51.

Monaco CL, Gootenberg DB, Zhao G, et al. Altered virome and bacterial microbiome in human immunodeficiency virus-associated acquired immunodeficiency syndrome. Cell Host Microbe. 2016;19:311–322.CrossRefPubMedPubMedCentral

52.

Tuddenham S, Sears CL. The intestinal microbiome and health. Curr Opin Infect Dis. 2015;28:464–470.CrossRefPubMedPubMedCentral

53.

Farhour Z, Mehraj V, Chen J, Ramendra R, Lu H, Routy JP. Use of (1– > 3)-beta-d-glucan for diagnosis and management of invasive mycoses in HIV-infected patients. Mycoses. 2018;61:718–722.CrossRefPubMedPubMedCentral

Titel: Gut Microbiome, Short-Chain Fatty Acids, and Mucosa Injury in Young Adults with Human Immunodeficiency Virus Infection
verfasst von: Yong Qing
Hangyu Xie
Chen Su
Youwei Wang
Qiuyue Yu
Qiuyu Pang
Fan Cui
Publikationsdatum: 17.12.2018
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 7/2019
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-018-5428-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Gut Microbiome, Short-Chain Fatty Acids, and Mucosa Injury in Young Adults with Human Immunodeficiency Virus Infection

Abstract

Background

Aims

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

At the Junction of Immunity and Barrier Function: The Immunomodulatory Protein TL1A May Also Regulate Intestinal Permeability

Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease

Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Chronic Hepatitis B in Korea

Competitive Endogenous RNA (ceRNA) Regulation Network of lncRNA–miRNA–mRNA in Colorectal Carcinogenesis

New Face of Hepatitis C

Anterograde Endoscopic Ultrasound-Guided Pancreatic Duct Drainage: A Technical Review

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin